Home/News/SS-31 (Elamipretide)

Mitochondrial Research

Cardiolipin-Targeting

SS-31 (Elamipretide): The Mitochondrial Peptide Deep Dive

SS-31 — known clinically as elamipretide — is one of the most studied mitochondria-targeting peptides. By binding cardiolipin in the inner mitochondrial membrane, it aims to restore the cellular energy machinery itself. Its story is a fascinating mix of elegant mechanism, genuine clinical promise, and the hard reality of trials that repeatedly missed their primary endpoints. Here is the full picture.

Research use only — not an approved drug. SS-31 / elamipretide is investigational and not FDA approved for any condition. Wellness claims about "cellular energy" or anti-aging are not supported by approved human evidence. This article is educational and not medical advice.

Also known as

Elamipretide, MTP-131, Bendavia

Drug class

Mitochondria-targeting peptide

FDA approved

No — under regulatory review

Target

Cardiolipin (inner mito membrane)

History & Discovery

~2004

Szeto-Schiller peptides discovered

SS-31 belongs to a family of aromatic-cationic tetrapeptides developed by Hazel Szeto and Peter Schiller at Cornell. Its sequence (D-Arg-2'6'-dimethyltyrosine-Lys-Phe-NH2) was engineered to be cell-permeable and to concentrate selectively in the inner mitochondrial membrane — an unusual targeting property for a peptide.

2000s

Cardiolipin as the target

Researchers identified that SS-31 binds cardiolipin, a phospholipid unique to the inner mitochondrial membrane that is essential for the structure of cristae and the efficiency of the electron transport chain. This explained how a single peptide could broadly improve mitochondrial bioenergetics.

2010s

Stealth BioTherapeutics develops elamipretide

The compound was licensed and developed clinically as elamipretide (also called MTP-131 and, in cardiac ischemia trials, Bendavia) by Stealth BioTherapeutics, targeting diseases driven by mitochondrial dysfunction.

2017–present

Clinical program across multiple diseases

Trials spanned primary mitochondrial myopathy, Barth syndrome, dry age-related macular degeneration, heart failure, and ischemia-reperfusion injury — with mixed results that defined both the promise and the limits of mitochondrial-targeted therapy.

Clinical Trial Evidence

MMPOWER-3 (Primary Mitochondrial Myopathy)

Phase 3

N: 218 adultsDuration: 24 weeks

The pivotal Phase 3 trial did NOT meet its primary endpoints (6-minute walk test and symptom score) in the overall population. A sobering result that highlighted how difficult mitochondrial disease endpoints are to move and measure.

TAZPOWER (Barth Syndrome)

Phase 2/3

N: Small genetic disorder cohortDuration: Crossover + open-label extension

The randomized crossover phase missed its primary endpoint, but the open-label extension reported improvements in functional and cardiac measures over longer treatment — forming the basis of the ongoing regulatory case for Barth syndrome.

ReCLAIM (Dry AMD / Geographic Atrophy)

Phase 1/2

N: Patients with age-related macular degenerationDuration: Up to 48 weeks

Early signals on certain retinal function and structural measures supported further study of mitochondrial protection in retinal disease, though it did not establish a definitive approvable benefit.

Cardiac / Heart Failure studies

Phase 2

N: VariousDuration: Acute and chronic designs

Studies in acute ischemia-reperfusion (as Bendavia) and heart failure with reduced ejection fraction produced inconsistent results, illustrating the gap between strong preclinical mitochondrial data and human clinical endpoints.

FDA Approval Process

Current status: not approved

SS-31 / elamipretide is NOT an FDA-approved drug. It remains investigational. Material sold as 'SS-31' for research is unapproved and unregulated, and is not a treatment for any condition.

Barth syndrome regulatory pathway

Stealth BioTherapeutics has pursued FDA approval of elamipretide for Barth syndrome — an ultra-rare genetic mitochondrial disease — using data from TAZPOWER and its open-label extension. The pathway has involved FDA advisory committee review and the complexities of demonstrating benefit in a tiny patient population where standard endpoints are hard to power.

Why mitochondrial drugs struggle at the FDA

Mitochondrial dysfunction underlies many diseases, but it is diffuse and hard to measure. Clinical endpoints (walk tests, symptom scales) are noisy, patient populations are small and heterogeneous, and biomarkers don't always translate to felt benefit. Several SS-31 trials missed primary endpoints despite coherent mechanistic data — a recurring theme in the field.

Mechanism of Action

Selective mitochondrial targeting

SS-31 is cell-permeable and, due to its alternating aromatic-cationic structure, accumulates 1,000–5,000-fold in the inner mitochondrial membrane without requiring a membrane potential — meaning it can reach even depolarized, damaged mitochondria.

Binding cardiolipin

It binds cardiolipin, the signature phospholipid of the inner membrane. Cardiolipin organizes the proteins of the electron transport chain and maintains the tightly folded cristae structure where ATP is produced. In disease and aging, cardiolipin becomes peroxidized and disorganized.

Stabilizing cristae & electron transport

By protecting cardiolipin, SS-31 helps preserve cristae architecture and the supercomplexes of the respiratory chain — improving electron flow, ATP synthesis efficiency, and reducing electron 'leak.'

Reducing reactive oxygen species

Less electron leak means fewer reactive oxygen species (ROS). SS-31 is therefore studied as both a bioenergetic enhancer and a targeted antioxidant — addressing the vicious cycle in which damaged mitochondria produce more ROS, which causes further damage.

Downstream Effects

Known / Documented

Improved mitochondrial respiration and ATP production in preclinical and ex vivo models
Reduced mitochondrial reactive oxygen species (targeted antioxidant effect)
Functional/cardiac improvements in the Barth syndrome open-label extension
Generally well tolerated in trials; injection site reactions are the most common adverse effect
Missed primary endpoints in several large trials (mitochondrial myopathy, some cardiac studies)

Speculative / Under Study

Anti-aging interest — mitochondrial decline is a hallmark of aging; human longevity data does not exist
Neuroprotection in neurodegenerative disease (preclinical interest, unproven clinically)
Kidney protection in acute injury and chronic kidney disease (preclinical models)
Skeletal muscle function and exercise capacity in aging (early research)
Retinal protection in macular degeneration (signals seen, not yet definitive)
Broad 'cellular energy' claims in the wellness market are not supported by approved human evidence